CClinicalTrials.gg
Active, not recruitingNCT03076034Updated Oct 28, 2025

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

An interventional study of Reference Point Indentation in Distal Radius Fracture, Osteoporosis and Hip Fractures, sponsored by Beth Israel Deaconess Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jan 2015, registered Mar 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
50 Years to 100 Years
Sex
All
01

Study summary

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA).

Read the detailed description

The objective of this study is to determine whether a new minimally invasive method for in vivo measurement of cortical bone tissue properties can identify those who are at risk for fragility fractures of the hip and radius. The investigators hypothesis is that women with fragility fractures of the hip and radius have altered cortical bone tissue properties compared to non-fracture controls independent of standard clinical tests, such as BMD. To test these hypotheses, The investigators propose two aims:

Aim 1: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with hip fractures and non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent hip fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with hip fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Aim 2: Compare cortical bone tissue properties as assessed in vivo by reference point indentation in women with distal radius fractures to non-fracture controls.

The investigators will compare cortical bone tissue material properties, as assessed by novel in vivo indentation at the mid-tibia in postmenopausal women with recent distal radius fractures (n) and age-similar controls without fractures (n=). In addition to in vivo indentation measurements, The investigators will assess hip and spine BMD by DXA; as well as other factors that may influence risk of fractures (e.g, vit D status, medication use and physical activity). Hypotheses: Postmenopausal women with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

Successful completion of this project will address the need to better assess bone mechanical properties at the tissue level in order to accurately predict fracture risk. The study will provide novel information about possible clinical utility of minimally invasive, in vivo bone indentation measurements to measure bone strength and its relationship to fracture risk.

Aim 3: An amendment to the protocol expanded the study population to now include males >50 years who present with distal radius fractures and those who present for a reason other than fracture (non-fracture controls). Hypotheses: Men >50 years with distal radius fractures will have worse bone tissue material properties compared to non-fracture controls even after adjustment for BMD and other potential confounders.

02

Conditions studied

  • Distal Radius Fracture
  • Osteoporosis
  • Hip Fractures
03

In context

Wrist Fractures

323 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.

This study's planned enrollment of 190 is above the median of 64 across 261 interventional studies indexed under Wrist Fractures.

Browse Wrist Fractures studies →

Lead sponsor

Beth Israel Deaconess Medical Center is the lead sponsor of 560 studies on the registry; 80 are open to participants now.

Of its 75 completed or terminated interventional studies of FDA-regulated products, 61 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Women with hip and wrist fractures within 2 weeks of presentation
  • Non-fracture controls

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo BMD by DXA or high-resolution peripheral quantitative computed tomography (HR-pQCT)
  • History of skeletal metastasis, primary hyperparathyroidism, Paget's disease, multiple myeloma
  • Treatment with bisphosphonate, estrogen (within previous 3 years), teriparatide therapy, calcitonin, selective estrogen receptor modulator (SERMs,within previous 3 years)
  • Use of glucocorticoids continuously for more than 3 months, use of anticonvulsants
  • Prior fracture in adulthood (>age 18) for healthy controls

Amendment to protocol added Arm 2, to include males >50 years with otherwise similar eligibility criteria.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Post-menopausal women

    We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

    Device: Reference Point Indentation

  • Experimental
    Males over 50 years

    We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.

    Device: Reference Point Indentation

Interventions

  • DeviceReference Point Indentation

    The "Osteoprobe": Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm.

    Also known as: Osteoprobe

06

What researchers measure

Primary outcomes

  1. Cortical bone tissue properties by reference point indentation

    Osteoprobe measurement

    Time frame: Day 1

  2. Bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA)

    DXA at the hip and spine

    Time frame: Day 1

07

Study locations

1 site
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
08

References and documents

Study documents

  • Informed consent form · Jan 9, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03076034
Lead sponsor
Beth Israel Deaconess Medical Center
Collaborators
Brigham and Women's Hospital
Responsible party
Tamara Rozental (Associate Professor, Harvard Medical School, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
Mar 9, 2017
Start date
Jan 26, 2015
Primary completion
Aug 8, 2026 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 28, 2025

Study contacts

Tamara Rozental, M.D.
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion